ORLANDO, Fla., April 30 -- SurgiLight Inc. has submitted the second 510(K) premarket notification for its EX-308 excimer laser for the phototherapy treatment of the skin disorder known as vitiligo. The EX-308 laser received its first clearance for the treatment of psoriasis in August of last year. "The results we have received thus far have been very encouraging and we intend to continue our research to further enhance the clinical results of the EX-308 and we are looking to expand the scope of our technology to include more applications," said J.T. Lin, president and CEO of SurgiLight. "We have recently signed an agreement with A & A Medical, a very well respected medical device manufacturer and we intend to begin marketing the EX-308 throughout the world soon. We also intend to place one of these systems with Advanced Medical Laser Services (AMLSI), our wholly owned mobile cosmetic center that services the southeast."